Dalteparin sodium injection + Warfarin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Deep-Vein Thrombosis
Conditions
Deep-Vein Thrombosis
Trial Timeline
Sep 1, 2002 → Dec 1, 2011
NCT ID
NCT00245856About Dalteparin sodium injection + Warfarin
Dalteparin sodium injection + Warfarin is a approved stage product being developed by Pfizer for Deep-Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00245856. Target conditions include Deep-Vein Thrombosis.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00245856 | Approved | Completed |
Competing Products
1 competing product in Deep-Vein Thrombosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Bristol Myers Squibb | Phase 2 | 35 |